Novartis Ag

Novartis Pharma Gmbh

Ulrich Beutler

Werner Zaugg

Prasad Koteswara Kapa

Michael John Girgis

Eric M Loeser

Guang-Pei Chen

Daniel Kaufmann

Gerhard Penn

Olivier Lohse

Peter Funfschilling

Peter Fünfschilling

Purification process for the preparation of the allylamine pharmaceutical terbinafine of formula I in free base form or acid addition salt form, by distilling crude terbinafine base, preferably by short path distillation, e.g. at a temperature above 100&#xb0; C. and reduced pressure, e.g. 0.2 mbar, and recovering the purified product in free base or acid addition salt form.

Purification process

A method for preparing an alkali metal salt comprising: (a) condensing a disilyloxydiene with an aldehyde in the presence of a titanium (IV) catalyst in an inert solvent to form a 5(S)-hydroxy-3-ketoester; (b) reducing the 5(S)-hydroxy-3-ketoester to a 3(R),5(S)-dihydroxyester in the presence of a di(lower alkyl)methoxyborane; and (c) hydrolyzing the 3(R),5(S)-dihydroxyester in the presence of an aqueous base to form an alkali metal salt.

Process for the manufacture of organic compounds

The invention relates to new processes for the preparation of the pharmaceutical oxcarbazepine, as well as novel intermediates prepared by or used for said processes, and the preparation of said intermediates.

Dibenzo [b,f]azepine intermediates

Growing community of inventors

Oberwil, Switzerland

Ulrich Beutler